DefinitionThis section has been translated automatically.
Interleukins (from Latin/Greek inter = between; leukos = white; kinein = to move) is the name given to a group of endogenous, short-chain regulatory proteins (cytokines) of the immune system (interleukin-1 to interleukin-38). Interleukins are mediators for induction, progression, and control of T-cell-mediated cytotoxic immune responses as well as B-cell activation (antibody production).
Interleukin-12 is a pleiotropic, heterodimeric protein whose two covalent subunits p35 and p40 are encoded by two different genes. The gene for the p35 subunit is located on chromosome 3 and the gene for the p40 subunit is located on chromosome 5. The p40 subunit contains a binding site for heparin. It is also a subunit of interleukin-23.
General informationThis section has been translated automatically.
The cytokine has a central function in the initiation and maintenance of a T-helper cell-1 (TH-1) - accentuated immune response (cellular defense).
Interleukin-12 is mainly produced by B lymphocytes after induction, mainly by bacteria or bacterial components (e.g. LPS, toxins) or by parasites. To a lesser extent, interleukin-12 is also produced by activated T lymphocytes, monocytes and macrophages.
The interleukin-12 receptor is expressed on activated CD4+ and CD8+ T lymphocytes and on NK cells.
IL-12 is ligand for a receptor consisting of 2 amino acid chains, IL-12Rbeta1 and IL-12Rbeta2. It is encoded by the IL12RB1 gene.
The interleukin-12 receptor is primarily expressed on B cells. It is also expressed on activated CD4+ and CD8+ T lymphocytes and on NK cells. Signals from the ligand-bound IL-12Rbeta2 complex are transduced via the JAK2 and TYK2 pathways. Mutations in this gene lead to immunodeficiency syndrome(Immunodeficiency 30).
Suppression of interleukin-12 production is mediated by cytokines such as type I interferons, interleukin-10, and TGF-beta, as well as by prostaglandin E2 .
Interleukin-12 activates antigen-presenting cells such as dendritic cells, especially those with a CD1c+ phenotype, as well as monocytes, macrophages, and neutrophilic granulocytes.
Interleukin-12 stimulates proliferation and cytotoxicity of activated NK cells, CD8+ and CD4+ T cells; furthermore of monocytes, macrophages and neutrophil granulocytes. In TH2 helper cells, it suppresses the production of interleukin-4, interleukin -5 and interleukin-10. Furthermore, interleukin-12 induces antiangiogenic cytokines (potential anti-tumor effect) and suppresses IgE production induced by interleukin-4. These effects are accompanied by IFN-gamma production.
Interleukin-12 induces the production of other cytokines and acts as an endogenous pyrogen along with interleukin-1 and TNFalpha.
Interleukin-12 influences the course of infectious diseases. Some microorganisms such as Candida albicans are able to inhibit interleukin-12.
Interleukin-12, along with interferon-gamma (IFN-γ) and IL-18, plays a key role in the development of Th1 cells. Thus, interleukin-12 influences a variety of immunological pathways; its general pathophysiological role can be defined as a broad Th1-type immune response against pathogens in general. Its potential role as a cancer therapeutic is of interest; a large number of publications are available on this topic.
You might also be interested in
General therapyThis section has been translated automatically.
Psoriasis and psoriatic arthritis: Interleukins 12 and 23 play a key role in plaque psoriasis and psoriatic arthritis, among other pro-inflammatory cytokines. Ustekinumab is a human IgG antibody that binds to the common p40 protein subunit of unbound interleukin-12 and -23. The complex thus prevents docking to the common receptor interleukin -12R on the surface of naive T cells.
Tumor diseases: Interleukin-12 shows several potent antitumor effects. It was obvious to use Interleukin-12 as a therapeutic agent for various tumor diseases due to its broad immunological effects. The cytokine does not directly inhibit tumor growth. Rather, Interleukin-12 is able to initiate a distinct Th1-type immune response to the tumor tissue. Severe side effects during systemic application and a very narrow therapeutic window have significantly dampened the original enthusiasm.
Kaposi's sarcoma: In this angiosarcoma the effects cannot yet be conclusively evaluated.
Cutaneous T-cell lymphoma: The results of interleukin-12 therapy in cutaneous T-cell lymphoma are not yet conclusive.
Note(s)This section has been translated automatically.
Possibly, interleukin-12 can activate repair enzymes that are able to repair damaged DNA.
LiteratureThis section has been translated automatically.
- Brunda MJ et al (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med178:1223-1230.
- Ferretti E et al (2010) Direct inhibition of human acute myeloid leukemia cell growth by IL-12, Immunol Lett 133:99-105.
- Golab J et al (2000) Direct stimulation of macrophages by IL-12 and IL-18-a bridge too far? Immunol Lett72:153-157.
- Hamza T et al (2010) Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 11:789-806.
- Hernandez-Alcoceba R et al (2016) Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12. immunotherapy 8:179-198 .
- Johnsson HJ et al (2015) Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis. Clin Exp Rheumatol 33(5 Suppl 93):S115-118.
- Judson MA et al (2011) Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. J Am Acad Dermatol 66:901-910
- Lasek W et al (2014) Interleukin 12: still a promising candidate for tumor immunotherapy? cancer immunol immunother 63:419-435.
- Méndez-Samperio P (2010) Role of interleukin-12 family cytokines in the cellular response to mycobacterial disease. Int J Infect Dis 14:e366-371.
- Ngiow SF et al (2013) A balance of interleukin-12 and -23 in cancer. Trends Immunol 34:548-555.
- Tang MM et al.(2013) Rapid downregulation of innate immune cells, interleukin-12 and interleukin-23 in generalized pustular psoriasis with infliximab in combination with acitretin. Dermatology 225:338-343.
- Tausend W et al (2014) Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg 18:156-169.
- Sun L et al (2015) Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease. Cytokines 75:249-255.
- Vignali DA et al.(2012) IL-12 family cytokines: immunological playmakers. Nat Immunol 13:722-728.https://www.ncbi.nlm.nih.gov/pubmed/22814351
- Wesa AK et al.(2001) IL-1 beta induces dendritic cells to produce IL-12 Int Immunol. 13:1053-1061.
- Zundler S et al.(2015) Interleukin-12: Functional activities and implications for disease. Cytokine Growth Factor Rev 26:559-568. https://www.ncbi.nlm.nih.gov/pubmed/26182974